T1	Competing_trial 1 146	articipation in another clinical trial at present or within 4 weeks of study entry. There may be exceptions at the discretion of the Investigator
T2	Condition 177 179	MS
T3	Qualifier 157 168	progressive
R1	Has_qualifier Arg1:T2 Arg2:T3	
T4	Condition 181 197	Hypersensitivity
T5	Drug 254 262	Lemtrada
R2	AND Arg1:T4 Arg2:T5	
T6	Post-eligibility 265 512	Medical, psychiatric, cognitive, or other conditions that, in the Investigator's opinion, compromise the patient's ability to understand the patient information, to give informed consent, to comply with the trial protocol, or to complete the study
T7	Post-eligibility 514 629	Any disability acquired from trauma or another illness that could interfere with evaluation of disability due to MS
T8	Post-eligibility 631 888	Major systemic disease or other illness that would, in the opinion of the Investigator, compromise patient safety or interfere with the interpretation of study results, e.g., current peptic ulcer disease or other conditions that may predispose to hemorrhage
T9	Condition 896 913	bleeding disorder
T10	Condition 921 938	dysfibrinogenemia
T11	Condition 940 960	factor IX deficiency
T12	Condition 962 972	hemophilia
T13	Condition 974 998	Von Willebrand's disease
T14	Condition 1000 1038	disseminated intravascular coagulation
T15	Condition 1040 1043	DIC
T16	Condition 1046 1067	fibrinogen deficiency
T17	Condition 1072 1098	clotting factor deficiency
*	OR T10 T11 T12 T13 T14 T16 T17
R3	Subsumes Arg1:T14 Arg2:T15	
T18	Scope 921 1098	dysfibrinogenemia, factor IX deficiency, hemophilia, Von Willebrand's disease, disseminated intravascular coagulation (DIC), fibrinogen deficiency, or clotting factor deficiency
R4	Subsumes Arg1:T9 Arg2:T18	
T19	Condition 1113 1131	autoimmune disease
T20	Condition 1161 1179	immune cytopenias,
T21	Condition 1180 1201	rheumatoid arthritis,
T22	Condition 1202 1230	systemic lupus erythematosus
T23	Condition 1238 1265	connective tissue disorders
T24	Condition 1267 1277	vasculitis
T25	Condition 1279 1305	inflammatory bowel disease
T26	Condition 1314 1323	psoriasis
T27	Qualifier 1307 1313	severe
R5	Has_qualifier Arg1:T26 Arg2:T27	
*	OR T26 T25 T24 T23 T22 T21 T20
T28	Scope 1161 1323	immune cytopenias, rheumatoid arthritis, systemic lupus erythematosus, other connective tissue disorders, vasculitis, inflammatory bowel disease, severe psoriasis
R6	Subsumes Arg1:T19 Arg2:T28	
T29	Condition 1336 1346	malignancy
T30	Negation 1348 1354	except
T31	Condition 1355 1380	basal skin cell carcinoma
R7	Has_negation Arg1:T31 Arg2:T30	
T32	Condition 1388 1408	psychiatric disorder
T33	Qualifier 1382 1387	Major
R8	Has_qualifier Arg1:T32 Arg2:T33	
T34	Qualifier 1421 1442	adequately controlled
T35	Negation 1417 1420	not
R9	Has_negation Arg1:T34 Arg2:T35	
R10	Has_qualifier Arg1:T32 Arg2:T34	
T36	Condition 1457 1475	Epileptic seizures
T37	Qualifier 1489 1510	adequately controlled
T38	Negation 1485 1488	not
R11	Has_negation Arg1:T37 Arg2:T38	
R12	Has_qualifier Arg1:T36 Arg2:T37	
T39	Condition 1532 1541	infection
T40	Qualifier 1525 1531	Active
R13	Has_qualifier Arg1:T39 Arg2:T40	
T41	Condition 1549 1570	deep-tissue infection
R14	Subsumes Arg1:T39 Arg2:T41	
T42	Observation 1700 1718	risk for infection
T43	Qualifier 1695 1699	high
R15	Has_qualifier Arg1:T42 Arg2:T43	
T44	Device 1726 1745	indwelling catheter
T45	Condition 1747 1756	dysphagia
T46	Condition 1762 1772	aspiration
T47	Condition 1774 1789	decubitus ulcer
T48	Condition 1808 1828	aspiration pneumonia
T49	Condition 1842 1865	urinary tract infection
T50	Qualifier 1832 1841	recurrent
*	OR T44 T45 T47 T48 T49
R16	AND Arg1:T45 Arg2:T46	
R17	Has_qualifier Arg1:T49 Arg2:T50	
T51	Scope 1726 1865	indwelling catheter, dysphagia with aspiration, decubitus ulcer, history of prior aspiration pneumonia or recurrent urinary tract infection
R18	Has_scope Arg1:T42 Arg2:T51	
T52	Measurement 1887 1915	human immunodeficiency virus
T53	Measurement 1917 1920	HIV
R19	Subsumes Arg1:T52 Arg2:T53	
T54	Value 1868 1882	Seropositivity
R20	Has_value Arg1:T52 Arg2:T54	
T55	Qualifier 1938 1955	hepatitis C Virus
T56	Condition 1923 1932	Infection
R21	Has_qualifier Arg1:T56 Arg2:T55	
T57	Condition 1973 1994	hepatitis B infection
T58	Measurement 2005 2025	hepatitis B serology
T59	Value 1996 2004	positive
R22	Has_value Arg1:T58 Arg2:T59	
R23	AND Arg1:T57 Arg2:T58	
T60	Qualifier 2050 2072	human cytomegaly virus
T61	Qualifier 2074 2078	HCMV
T62	Qualifier 2081 2099	Epstein-Barr virus
T63	Qualifier 2101 2104	EBV
T64	Qualifier 2107 2129	varicella-zoster virus
T65	Qualifier 2131 2134	VZV
T66	Condition 2035 2044	infection
T67	Qualifier 2028 2034	Active
R24	Has_qualifier Arg1:T66 Arg2:T67	
T68	Scope 2050 2135	human cytomegaly virus (HCMV), Epstein-Barr virus (EBV), varicella-zoster virus (VZV)
R25	Subsumes Arg1:T60 Arg2:T61	
R26	Subsumes Arg1:T62 Arg2:T63	
R27	Subsumes Arg1:T64 Arg2:T65	
*	OR T60 T62 T64
R28	Has_scope Arg1:T66 Arg2:T68	
T69	Condition 2137 2156	Latent tuberculosis
T70	Negation 2157 2163	unless
T71	Procedure 2174 2199	anti-tuberculosis therapy
T72	Qualifier 2209 2218	completed
R29	Has_negation Arg1:T72 Arg2:T70	
R30	Has_qualifier Arg1:T71 Arg2:T72	
R31	AND Arg1:T69 Arg2:T71	
T73	Condition 2223 2242	active tuberculosis
*	OR T69 T73
T74	Condition 2254 2271	fungal infections
T75	Qualifier 2245 2253	Invasive
R32	Has_qualifier Arg1:T74 Arg2:T75	
T76	Measurement 2299 2316	Cervical cytology
T77	Negation 2317 2322	other
T78	Qualifier 2328 2333	PAP I
T79	Qualifier 2337 2343	PAP II
T80	Qualifier 2345 2357	Papanicolaou
*	OR T78 T79 T80
T82	Qualifier 2381 2401	human papillomavirus
T83	Qualifier 2362 2380	cervical high risk
T84	Qualifier 2403 2406	HPV
R35	Subsumes Arg1:T82 Arg2:T84	
R36	Has_qualifier Arg1:T82 Arg2:T83	
T85	Value 2408 2418	positivity
T86	Value 0 13	Participation
R37	Has_value Arg1:T76 Arg2:T85	
T87	Scope 2317 2407	other than PAP I or PAP II (Papanicolaou) or cervical high risk human papillomavirus (HPV)
T88	Scope 2328 2358	PAP I or PAP II (Papanicolaou)
R38	Has_negation Arg1:T88 Arg2:T77	
T89	Scope 2362 2407	cervical high risk human papillomavirus (HPV)
*	OR T88 T89
R39	Has_scope Arg1:T76 Arg2:T87	
T81	Condition 2430 2437	illness
T90	Condition 2441 2450	infection
T91	Qualifier 2452 2458	latent
T92	Qualifier 2462 2468	active
*	OR T91 T92
T93	Temporal 2462 2468	active
R33	multi Arg1:T92 Arg2:T93	
T94	Non-representable 2476 2505	in the Investigator's opinion
T95	Qualifier 2516 2547	exacerbated by study medication
T96	Drug 2531 2547	study medication
R34	multi Arg1:T95 Arg2:T96	
R40	AND Arg1:T95 Arg2:T94	
*	OR T90 T81
T97	Scope 2452 2468	latent or active
T98	Scope 2430 2450	illness or infection
R41	Has_scope Arg1:T98 Arg2:T97	
R42	Has_qualifier Arg1:T98 Arg2:T95	
T99	Measurement 2549 2573	Differential blood count
T100	Value 2574 2603	< lower limit of normal (LLN)
R43	Has_value Arg1:T99 Arg2:T100	
T101	Temporal 2604 2616	at Screening
R44	Has_temporal Arg1:T99 Arg2:T101	
T102	Measurement 2628 2642	platelet count
T103	Qualifier 2618 2627	Confirmed
R45	Has_qualifier Arg1:T102 Arg2:T103	
T104	Value 2643 2681	< the LLN of the evaluating laboratory
T105	Temporal 2682 2694	at Screening
T106	Value 2712 2723	<100,000/µL
T107	Temporal 2724 2744	within the past year
R48	Has_temporal Arg1:T106 Arg2:T107	
R46	Has_temporal Arg1:T104 Arg2:T105	
*	OR T104 T106
T108	Qualifier 2750 2782	sample without platelet clumping
T109	Scope 2643 2744	< the LLN of the evaluating laboratory at Screening or documented at <100,000/µL within the past year
R47	Has_scope Arg1:T102 Arg2:T109	
R49	Has_qualifier Arg1:T102 Arg2:T108	
T110	Value 2800 2813	above the ULN
T111	Value 2784 2792	Presence
T112	Measurement 2818 2882	anti-thyroid stimulating hormone receptor antibodies (anti-TSHR)
R50	Subsumes Arg1:T111 Arg2:T110	
T113	Measurement 2887 2930	anti-thyroid peroxidase antibody (anti-TPO)
T114	Scope 2818 2930	anti-thyroid stimulating hormone receptor antibodies (anti-TSHR) and anti-thyroid peroxidase antibody (anti-TPO)
R51	Has_value Arg1:T114 Arg2:T111	
T115	Drug 2932 2943	Vaccination
T116	Temporal 2944 2994	less than 6 weeks prior to treatment with Lemtrada
T117	Reference_point 2971 2994	treatment with Lemtrada
T118	Procedure 2971 2980	treatment
T119	Drug 2986 2994	Lemtrada
R52	AND Arg1:T118 Arg2:T119	
R53	multi Arg1:T117 Arg2:T118	
R54	Has_index Arg1:T116 Arg2:T117	
R55	AND Arg1:T116 Arg2:T115	
T120	Procedure 2997 3006	Treatment
T121	Drug 3012 3026;3048 3053	antineoplastic drugs
T122	Drug 3030 3053	immunosuppressive drugs
*	OR T122 T121
T123	Temporal 3054 3093	within 8 weeks prior to study inclusion
T124	Reference_point 3078 3093	study inclusion
R56	Has_index Arg1:T123 Arg2:T124	
T125	Scope 3012 3053	antineoplastic or immunosuppressive drugs
R57	Has_scope Arg1:T120 Arg2:T125	
*	OR T120 T123
T126	Drug 3110 3132	pulsed corticosteroids
T127	Observation 3147 3157	history of
T128	Condition 3158 3175	steroid psychosis
T129	Condition 3095 3106	Intolerance
R59	Has_temporal Arg1:T128 Arg2:T127	
R58	AND Arg1:T129 Arg2:T126	
*	OR T129 T128
T130	Condition 3177 3201	Inability to undergo MRI
T131	Procedure 3198 3201	MRI
T132	Drug 3207 3217	gadolinium
R60	AND Arg1:T131 Arg2:T132	
T133	Mood 3177 3189	Inability to
R61	Has_mood Arg1:T131 Arg2:T133	
R62	multi Arg1:T130 Arg2:T131	
T134	Person 3237 3259	childbearing potential
T135	Value 3267 3275	positive
T136	Measurement 3276 3296	serum pregnancy test
T137	Condition 3298 3306	pregnant
T138	Condition 3310 3319	lactating
*	OR T137 T138 T134
R63	Has_value Arg1:T136 Arg2:T135	
R64	AND Arg1:T134 Arg2:T136	
T139	Person 3321 3327	Female
T140	Person 3340 3362	childbearing potential
T141	Scope 3321 3362	Female patients of childbearing potential
A1	Optional T141
T142	Pregnancy_considerations 3364 3728	Unwilling to agree to use a reliable and acceptable contraceptive method (Pearl index <1) throughout the study period. These methods include: hormone releasing intrauterine device (IUD), hormonal-based contraception, surgical sterilization, abstinence, or double-barrier contraception (condom and occlusive cap [diaphragm or cervical cap combined with spermicide])
R65	AND Arg1:T141 Arg2:T142	
